Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • ipragliflozin

    market access in Japan

    Implementation of Cost-Effectiveness Analysis in Japan’s Health Technology Assessment Process

    Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new medicines and medical devices. Introduced as part of a broader health technology assessment (HTA)...

    Petauri Evidence

    - PMLiVE

    Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

    The company is planning to submit regulatory applications for the candidate by the end of the year

    regeneron headquarters

    Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

    The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

    - PMLiVE

    Eli Lilly announces $3bn expansion to US injectables manufacturing facility

    The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines

    - PMLiVE

    Sanofi unveils plans to build €1bn insulin production base in China

    The site will focus on serving the insulin medication needs of local diabetic patients

    - PMLiVE

    Astellas’ Vyloy approved by FDA as first-line gastric cancer combination treatment

    Approximately 26,890 new cases of gastric cancer will be diagnosed in the US this year

    - PMLiVE

    Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval

    About 614,000 people are diagnosed with bladder cancer globally every year

    - PMLiVE

    Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn

    Frontotemporal dementia accounts for less than one in 30 cases of the neurodegenerative disorder

    - PMLiVE

    Astellas’ Vyloy combination approved by EC as first-line gastric cancer treatment

    Approximately 136,000 cases of the disease are diagnosed in Europe every year

    - PMLiVE

    Common antidiabetic drug metformin found to slow growth of precancerous cells

    The findings suggest that the drug could be used to manage squamous oesophageal cancer risk

    - PMLiVE

    Eli Lilly’s once-weekly insulin candidate shows promise in late-stage diabetes trials

    It is hoped that a once-weekly treatment option could improve adherence rates

    - PMLiVE

    Merck and Astellas/Pfizer’s bladder cancer combination granted EC approval

    Bladder cancer is the fifth most commonly diagnosed cancer in Europe, with more than 165,000 annual cases

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links